# Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

Source: https://onco.cc/trials/nct06011109/  
OnCo record `nct06011109` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of APG-157 in glioma & glioblastoma, run by Aveta Biomics, Inc., active and no longer recruiting.

## Summary

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab is a phase 1/2 interventional study registered as NCT06011109 by Aveta Biomics, Inc., with 30 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: APG-157.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-19
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06011109
- Phase: 1/2
- Setting: A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma
- Sponsor: Aveta Biomics, Inc.
- Enrolled: 30

## Notes

- Registry status on 19 October 2026: Active, not recruiting (registry record last updated 5 October 2026; primary completion expected 31 December 2026).

## Sources

- ClinicalTrials.gov NCT06011109: https://clinicaltrials.gov/study/NCT06011109

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- companies: [Aveta Biomics](https://onco.cc/companies/aveta-biomics/)

---
JSON: https://onco.cc/api/v1/entities/nct06011109.json